Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Core Insights - Insmed Incorporated will present six abstracts from the Phase 3 ASPEN study of BRINSUPRI (brensocatib) at the CHEST 2025 conference, highlighting its efficacy and potential impact on patients with non-cystic fibrosis bronchiectasis [1][3] Company Overview - Insmed is a global biopharmaceutical company focused on delivering innovative therapies for serious diseases, with a commitment to patient-first approaches [1][18] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [18] Product Information - BRINSUPRI (brensocatib) is a small molecule, once-daily oral treatment indicated for non-cystic fibrosis bronchiectasis in patients aged 12 and older [6][17] - The drug works by inhibiting neutrophil serine proteases, which are key drivers of chronic airway inflammation in bronchiectasis [6] Clinical Study Details - The ASPEN study was a global, randomized, double-blind, placebo-controlled Phase 3 trial involving over 1,700 patients across 391 sites in 35 countries [7] - The study evaluated the efficacy, safety, and tolerability of brensocatib, with a focus on symptom burden and structural lung changes [2][7] Upcoming Presentations - Presentations at CHEST 2025 will include analyses on the effects of brensocatib on symptom burden, CT outcomes, and its efficacy in patients with comorbid conditions like COPD [2][5] - Specific presentations will cover various subgroups, including Asian populations and patients experiencing pulmonary exacerbations [5][2]